{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T16:01:39Z","timestamp":1781971299254,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T00:00:00Z","timestamp":1459123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40261-016-0395-x","type":"journal-article","created":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T10:09:47Z","timestamp":1459159787000},"page":"491-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study"],"prefix":"10.1007","volume":"36","author":[{"given":"Luis","family":"Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Recinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bezner","family":"Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Rovelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny Elizabeth","family":"Elias Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Calder\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Pomata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Ver\u00f3nica","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Perez-Lloret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,28]]},"reference":[{"key":"395_CR1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00023210-200923030-00007","volume":"23","author":"CM Baldwin","year":"2009","unstructured":"Baldwin CM, Scott LJ. Quetiapine extended release: in schizophrenia. CNS Drugs. 2009;23:261\u20139.","journal-title":"CNS Drugs"},{"key":"395_CR2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1586\/14737175.2013.846519","volume":"13","author":"R Weisler","year":"2013","unstructured":"Weisler R, McIntyre RS, Bauer M. Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. Expert Rev Neurother. 2013;13:1183\u2013200.","journal-title":"Expert Rev Neurother"},{"key":"395_CR3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/11597330-000000000-00000","volume":"32","author":"AC Altamura","year":"2012","unstructured":"Altamura AC, Moliterno D, Paletta S, et al. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. Clin Drug Investig. 2012;32:213\u20139.","journal-title":"Clin Drug Investig"},{"key":"395_CR4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-0033-1363258","volume":"47","author":"V Selle","year":"2014","unstructured":"Selle V, Schalkwijk S, Vazquez GH, et al. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47:43\u201352.","journal-title":"Pharmacopsychiatry"},{"key":"395_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9758\/cpn.2014.12.1.1","volume":"12","author":"K Hatta","year":"2014","unstructured":"Hatta K, Ito H. Strategies for early non-response to antipsychotic drugs in the treatment of acute-phase schizophrenia. Clin Psychopharmacol Neurosci. 2014;12:1\u20137.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"395_CR6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2014.07.015","volume":"158","author":"K Hatta","year":"2014","unstructured":"Hatta K, Otachi T, Fujita K, et al. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. Schizophr Res. 2014;158:213\u201322.","journal-title":"Schizophr Res"},{"key":"395_CR7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/BF02245602","volume":"124","author":"BJ Kinon","year":"1996","unstructured":"Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology. 1996;124:2\u201334.","journal-title":"Psychopharmacology"},{"key":"395_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pnpbp.2009.12.001","volume":"34","author":"S Nakajima","year":"2010","unstructured":"Nakajima S, Suzuki T, Watanabe K, et al. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:259\u201364.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"395_CR9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/YIC.0000000000000012","volume":"29","author":"CU Pae","year":"2014","unstructured":"Pae CU, Wang SM, Han C, et al. Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. Int Clin Psychopharmacol. 2014;29:116\u20139.","journal-title":"Int Clin Psychopharmacol"},{"key":"395_CR10","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.2147\/NDT.S49944","volume":"9","author":"S Gopal","year":"2013","unstructured":"Gopal S, Liu Y, Alphs L, et al. Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. Neuropsychiatr Dis Treat. 2013;9:1381\u201392.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"395_CR11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clinthera.2009.03.002","volume":"31","author":"C Datto","year":"2009","unstructured":"Datto C, Berggren L, Patel JB, et al. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther. 2009;31:492\u2013502.","journal-title":"Clin Ther"},{"key":"395_CR12","doi-asserted-by":"crossref","first-page":"s7","DOI":"10.1192\/bjp.191.50.s7","volume":"50","author":"AM Mortimer","year":"2007","unstructured":"Mortimer AM. Symptom rating scales and outcome in schizophrenia. Br J Psychiatry Suppl. 2007;50:s7\u201314.","journal-title":"Br J Psychiatry Suppl"},{"key":"395_CR13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQoL Group","year":"1990","unstructured":"EuroQoL Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"395_CR14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348\u201354.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"395_CR15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1192\/bjp.bp.109.070961","volume":"197","author":"A Pope","year":"2010","unstructured":"Pope A, Adams C, Paton C, et al. Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. Br J Psychiatry. 2010;197:67\u201372.","journal-title":"Br J Psychiatry"},{"key":"395_CR16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540\u20135.","journal-title":"Sleep"},{"key":"395_CR17","volume-title":"Guidelines for ATC classification and DDD assignment 2012","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2011","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo: World Health Organization; 2011."},{"key":"395_CR18","volume-title":"International textbook of obesity","author":"L Breum","year":"2001","unstructured":"Breum L, Fernstrom H. Drug-induced obesity. In: Bjorntorp P, editor. International textbook of obesity. New York: Wiley; 2001."},{"key":"395_CR19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1358\/dot.2005.41.8.893630","volume":"41","author":"R Ness-Abramof","year":"2005","unstructured":"Ness-Abramof R, Apovian CM. Drug-induced weight gain. Drugs Today (Barc). 2005;41:547\u201355.","journal-title":"Drugs Today (Barc)"},{"key":"395_CR20","first-page":"391","volume":"79","author":"JF Pagel","year":"2009","unstructured":"Pagel JF. Excessive daytime sleepiness. Am Fam Physician. 2009;79:391\u20136.","journal-title":"Am Fam Physician"},{"key":"395_CR21","volume-title":"Uncommon causes of movement disorders","author":"S Perez-Lloret","year":"2011","unstructured":"Perez-Lloret S, Merello M. Tardive dyskinesias and other drug-induced movement disorders. In: G\u00e1lvez-Jim\u00e9nez N, Tuite PJ, editors. Uncommon causes of movement disorders. Cambdrige: Cambridge University Press; 2011."},{"key":"395_CR22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4306\/pi.2013.10.4.407","volume":"10","author":"SH Jung","year":"2013","unstructured":"Jung SH, Yoon JS, Ahn YM, et al. Influencing factors and predictors of early response in schizophrenia patients receiving the paliperidone extended-release tablets (paliperidone ER). Psychiatry Investig. 2013;10:407\u201316.","journal-title":"Psychiatry Investig"},{"key":"395_CR23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/JCP.0b013e3181dcb7c3","volume":"30","author":"BJ Kinon","year":"2010","unstructured":"Kinon BJ, Chen L, Stauffer VL, et al. Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials. J Clin Psychopharmacol. 2010;30:286\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"395_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-244X-11-23","volume":"11","author":"SJ Ruberg","year":"2011","unstructured":"Ruberg SJ, Chen L, Stauffer V, et al. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2011;11:23.","journal-title":"BMC Psychiatry"},{"key":"395_CR25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11533060-000000000-00000","volume":"30","author":"CU Pae","year":"2010","unstructured":"Pae CU, Chiesa A, Mandelli L, et al. Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. Clin Drug Investig. 2010;30:187\u201393.","journal-title":"Clin Drug Investig"},{"key":"395_CR26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.npp.1300341","volume":"29","author":"MM Katz","year":"2004","unstructured":"Katz MM, Tekell JL, Bowden CL, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004;29:566\u201379.","journal-title":"Neuropsychopharmacology"},{"key":"395_CR27","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jpsychires.2013.05.020","volume":"47","author":"C Fabbri","year":"2013","unstructured":"Fabbri C, Marsano A, Balestri M, et al. Clinical features and drug induced side effects in early versus late antidepressant responders. J Psychiatr Res. 2013;47:1309\u201318.","journal-title":"J Psychiatr Res"},{"key":"395_CR28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pnpbp.2013.02.009","volume":"44","author":"B Crespo-Facorro","year":"2013","unstructured":"Crespo-Facorro B, de la Foz VO, Ayesa-Arriola R, et al. Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP study. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:162\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"395_CR29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/PPA.S2940","volume":"2","author":"H Ascher-Svanum","year":"2008","unstructured":"Ascher-Svanum H, Zhu B, Faries DE, et al. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence. 2008;2:67\u201377.","journal-title":"Patient Prefer Adherence"},{"key":"395_CR30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-244X-12-99","volume":"12","author":"A Berger","year":"2012","unstructured":"Berger A, Edelsberg J, Sanders KN, et al. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study. BMC Psychiatry. 2012;12:99.","journal-title":"BMC Psychiatry"},{"key":"395_CR31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/23.4.637","volume":"23","author":"WS Fenton","year":"1997","unstructured":"Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637\u201351.","journal-title":"Schizophr Bull"},{"key":"395_CR32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1176\/ps.62.9.pss6209_1032","volume":"62","author":"KL Rascati","year":"2011","unstructured":"Rascati KL, Richards KM, Ott CA, et al. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv. 2011;62:1032\u201340.","journal-title":"Psychiatr Serv"},{"key":"395_CR33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hup.1091","volume":"25","author":"D Meulien","year":"2010","unstructured":"Meulien D, Huizar K, Brecher M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2010;25:103\u201315.","journal-title":"Hum Psychopharmacol"},{"key":"395_CR34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2165\/00023210-200115070-00004","volume":"15","author":"JM Russell","year":"2001","unstructured":"Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs. 2001;15:537\u201351.","journal-title":"CNS Drugs"},{"key":"395_CR35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11632020-000000000-00000","volume":"26","author":"A Attard","year":"2012","unstructured":"Attard A, Taylor DM. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? CNS Drugs. 2012;26:491\u2013508.","journal-title":"CNS Drugs"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0395-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0395-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0395-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:57Z","timestamp":1559503737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0395-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,28]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0395-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,28]]}}}